In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• cVDPV2 detections in Burundi and the DRC (PGEI)
• Novel oral polio vaccine type 2 story (The Lancet)
• Prior COVID-19 infection associated with risk of diagnosed erectile dysfunction (IJIR)
• Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection (BMJ) 
• Protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals(The Lancet)
• Effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths (The Lancet)
• Projected COVID-19 mortality reduction from Paxlovid rollout (JAMA)
• SARS-CoV-2 mRNA vaccines decouple anti-viral immunity (Nature) 
• Contribute to our ASTMH fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 994
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]